Skip to main content

Table 1 Patientsā€™ characteristics (167 evaluable patients for the clinical analysis)

From: ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations

Ā 

Patients number (%)

Gender

ā€ƒMale

106 (63.5)

ā€ƒFemale

61 (36.5)

Cancer familiarity

ā€ƒYes

101 (60.5)

ā€ƒNo

43 (25.7)

ā€ƒUnknown

23 (13.8)

Comorbidity

ā€ƒYes

52 (31.1)

ā€ƒNo

115 (68.9)

Performance Status sec. ECOG

ā€ƒ0

99 (59.3)

ā€ƒ1

36 (21.6)

ā€ƒ2ā€“3

12 (7.1)

ā€ƒUnknown

20 (12.0)

Histology

ā€ƒAdenocarcinoma

147 (88.0)

ā€ƒSquamous

7 (4.2)

ā€ƒOther/Mixed

13 (7.8)

T descriptor according to TNM

ā€ƒ1ā€“2

102 (61.1)

ā€ƒ3ā€“4

65 (39.9)

N descriptor according to TNM

ā€ƒ0

36 (21.6)

ā€ƒ1

19 (11.4)

ā€ƒ2

66 (39.5)

ā€ƒ3

46 (27.5)

M descriptor according to TNM

ā€ƒ0

66 (39.5)

ā€ƒ1

101 (60.5)

Disease stage

ā€ƒI-II

36 (21.6)

ā€ƒIII-IV

131 (78.4)

Grading

ā€ƒ1

12 (7.2)

ā€ƒ2

15 (9.0)

ā€ƒ3

42 (25.1)

ā€ƒUnknown

98 (58.7)

Smoking status

ā€ƒCurrent

56 (33.5)

ā€ƒFormer

68 (40.7)

ā€ƒNever

34 (20.4)

ā€ƒUnknown

9 (5.4)

Starting treatment

ā€ƒSurgery

47 (28.1)

ā€ƒNeoadjuvant

3 (1.8)

ā€ƒChemo-radiotherapy

17 (10.2)

ā€ƒChemotherapy

75 (44.9)

ā€ƒSupport therapy

25 (15.0)

Response rate to 1st line therapy

ā€ƒCR

3 (1.8)

ā€ƒPR

31 (18.6)

ā€ƒSD

20 (12.0)

ā€ƒPD

35 (21.0)

ā€ƒNP

78 (46.6)

ALK-CNG

ā€ƒdisomic

71 (42.5)

ā€ƒ3ā€“7 copies

42 (25.1)

ā€ƒ>7 copies

15 (9.0)

ā€ƒNA

39 (23.4)

  1. CR complete response, PR partial response, SD stable disease, PD progressive disease, NP not performed, CNG copy number gain, NA not available